2,757 reports of this reaction
2.1% of all LAMOTRIGINE EXTENDED RELEASE reports
#10 most reported adverse reaction
RASH is the #10 most commonly reported adverse reaction for LAMOTRIGINE EXTENDED RELEASE, manufactured by Advagen Pharma Limited. There are 2,757 FDA adverse event reports linking LAMOTRIGINE EXTENDED RELEASE to RASH. This represents approximately 2.1% of all 130,110 adverse event reports for this drug.
Patients taking LAMOTRIGINE EXTENDED RELEASE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for LAMOTRIGINE EXTENDED RELEASE, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for LAMOTRIGINE EXTENDED RELEASE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 2,757 FDA reports for LAMOTRIGINE EXTENDED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.1% of all adverse event reports for LAMOTRIGINE EXTENDED RELEASE, making it a notable side effect.
If you experience rash while taking LAMOTRIGINE EXTENDED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.